Homepage>Company>Media>Pharma News>2018>Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint